These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29326485)

  • 21. A Global Approach to Rare Diseases Research and Orphan Products Development: The International Rare Diseases Research Consortium (IRDiRC).
    Cutillo CM; Austin CP; Groft SC
    Adv Exp Med Biol; 2017; 1031():349-369. PubMed ID: 29214582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
    Schlander M; Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A human-on-a-chip approach to tackling rare diseases.
    de Mello CPP; Rumsey J; Slaughter V; Hickman JJ
    Drug Discov Today; 2019 Nov; 24(11):2139-2151. PubMed ID: 31412288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new toolkit for conducting clinical trials in rare disorders.
    Abrahamyan L; Diamond IR; Johnson SR; Feldman BM
    J Popul Ther Clin Pharmacol; 2014; 21(1):e66-78. PubMed ID: 24671886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of orphan drug policies in treating rare diseases.
    Weerasooriya SU
    Health Info Libr J; 2019 Jun; 36(2):179-184. PubMed ID: 30933412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 28. Do we need authorized orphan drugs when compounded medications are available?
    Dooms M; Pincé H; Simoens S
    J Clin Pharm Ther; 2013 Feb; 38(1):1-2. PubMed ID: 22973866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The challenges of pharmacoepidemiology of orphan drugs in rare diseases.
    Lapeyre-Mestre M
    Therapie; 2020 Apr; 75(2):215-220. PubMed ID: 32164974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global effort against rare and orphan diseases.
    Harari S; Cottin V; Humbert M
    Eur Respir Rev; 2012 Sep; 21(125):171-2. PubMed ID: 22941880
    [No Abstract]   [Full Text] [Related]  

  • 31. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare diseases: the bane of modern society and the quest for cures.
    Azie N; Vincent J
    Clin Pharmacol Ther; 2012 Aug; 92(2):135-9. PubMed ID: 22814654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Worldwide collaboration for orphan drug designation.
    Mariz S; Reese JH; Westermark K; Greene L; Goto T; Hoshino T; Llinares-Garcia J; Sepodes B
    Nat Rev Drug Discov; 2016 Jun; 15(6):440-1. PubMed ID: 27245396
    [No Abstract]   [Full Text] [Related]  

  • 37. Ethical dilemmas about orphan drugs for orphan diseases.
    Isaacs D
    J Paediatr Child Health; 2014 Apr; 50(4):249-50. PubMed ID: 24698059
    [No Abstract]   [Full Text] [Related]  

  • 38. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
    Maeda K; Kaneko M; Narukawa M; Arato T
    Orphanet J Rare Dis; 2017 Aug; 12(1):143. PubMed ID: 28835285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethical dilemmas about orphan drugs for orphan diseases.
    Gunasekera H
    J Paediatr Child Health; 2014 Aug; 50(8):656. PubMed ID: 25080986
    [No Abstract]   [Full Text] [Related]  

  • 40. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.